ライフサイエンスコーパス: renal replacement therapy

1 us system, or death), and interventions (ie, renal replacement therapy).

2 the baseline value or a new requirement for renal replacement therapy).

3 unction, none have shown efficacy apart from renal replacement therapy.

4 septic acute kidney injury courses requiring renal replacement therapy.

5 kidney injury during prolonged intermittent renal replacement therapy.

6 septic acute kidney injury with the need for renal replacement therapy.

7 ney injury and may be worsened by the use of renal replacement therapy.

8 t useful as a trigger to initiate continuous renal replacement therapy.

9 constrictive therapy and decisions regarding renal replacement therapy.

10 seline 3 days before the start of continuous renal replacement therapy.

11 r respiratory support, and five and nine for renal replacement therapy.

12 Nineteen patients required renal replacement therapy.

13 ents and is often associated with a need for renal replacement therapy.

14 Critically ill adults requiring continuous renal replacement therapy.

15 rate and end stage kidney disease requiring renal replacement therapy.

16 w rate influences circuit life in continuous renal replacement therapy.

17 atinine was >1.2mg/dL or they were receiving renal replacement therapy.

18 eft ventricular mechanical assist device, or renal replacement therapy.

19 ess than 10 mL/min/1.73 m2, or initiation of renal replacement therapy.

20 al citrate anticoagulation during continuous renal replacement therapy.

21 d balance, however, was attenuated by use of renal replacement therapy.

22 rates of 250 or 150 mL/min during continuous renal replacement therapy.

23 Continuous renal replacement therapy.

24 ve and was treated with repeated sessions of renal replacement therapy.

25 end-stage kidney disease (ESKD) and need for renal replacement therapy.

26 e develop end-stage renal disease, requiring renal replacement therapy.

27 tilation hours of 130 and one third required renal replacement therapy.

28 d the rate of acute kidney injury and use of renal replacement therapy.

29 y composite outcome of hospital mortality or renal replacement therapy.

30 ent of renal function and discontinuation of renal replacement therapy.

31 herapy, including mechanical ventilation and renal replacement therapy.

32 received vasopressors and 79 (31%) received renal replacement therapy.

33 RE-II mortality probability and the need for renal replacement therapy.

34 icate decision of whether or not to initiate renal replacement therapy.

35 al activity in patients requiring continuous renal replacement therapy.

36 ts with severe acute kidney injury requiring renal replacement therapy.

37 GFR of 30% or more from baseline, or chronic renal replacement therapy.

38 easible in ICU patients requiring continuous renal replacement therapy.

39 th antibiotic doses often used in continuous renal replacement therapy.

40 ore and 0.75 (0.39-1.44; p=0.39) for chronic renal replacement therapy.

41 ute kidney injury patients with the need for renal replacement therapy.

42 increased use of mechanical ventilation and renal-replacement therapy.

43 to either an early or a delayed strategy of renal-replacement therapy.

44 n the delayed-strategy group did not receive renal-replacement therapy.

45 and a delayed strategy for the initiation of renal-replacement therapy.

46 t option for HIV-infected patients requiring renal-replacement therapy.

47 I treated with potentially lactate-depleting renal replacement therapies.

48 [13.0, 29.5] ng/mL; P = 0.002), and need for renal replacement therapy (16.5 [11.3, 23.6] ng/mL vs. 2

49 ions may use hemodialysis (1D) or continuous renal replacement therapy (1D).

50 cal ventilation; 5 (19%) received continuous renal-replacement therapy; 22 (81%) received empirical a

51 Of the children managed with continuous renal replacement therapy, 26 (58%) survived: 19 were su

52 lacement therapy compared with those without renal replacement therapy (47.3% vs 71.8%; p < 0.001) ov

53 sor support (79.4% vs 55.0%; p < 0.001), and renal replacement therapy (48.8% vs 22.1%; p < 0.001).

54 1), vasopressors (23.2% vs 10.9%; P < .001), renal replacement therapy (49.6% vs 30.3%; P < .001), an

55 rates of mechanical ventilation (23.2%) and renal replacement therapy (6.6%) but the lowest rates of

56 echanical support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01).

57 ing remote ischemic preconditioning received renal replacement therapy (7 [5.8%] vs 19 [15.8%]; absol

58 During continuous renal replacement therapy, a high net ultrafiltration ra

59 stigate (a) the extent to which age at first renal replacement therapy, achievement of developmental

60 te renal failure were analyzed: the need for renal replacement therapy, acute kidney injury incidence

61 tio, 1.33; 95% CI, 1.02-1.74; p = 0.03), and renal replacement therapy (adjusted odds ratio, 1.49; 95

62 s ratio, 1.01; 95% CI, 1.00-1.03; p = 0.02), renal replacement therapy (adjusted odds ratio, 1.81; 95

63 7-day AKI, or on the need for postoperative renal replacement therapy after adjustments for confound

64 le-traumatic and non-traumatic AKI requiring renal replacement therapy (AKI-RRT).

65 However, diurnal variation, continuous renal replacement therapy and drug-interference could co

66 tus at hospital discharge, examined rates of renal replacement therapy and fluid overload, and measur

67 imiting the duration of PD as a modality for renal replacement therapy and increasing patient morbidi

68 gs use is associated with a reduced need for renal replacement therapy and lower acute kidney injury

69 ables were thrombocytopenia at initiation of renal replacement therapy and platelet decrease followin

70 me was the need for organ support, including renal replacement therapy and/or for inotrope(s) and/or

71 ion, 30% required vasopressors, 17% required renal replacement therapy, and 28% had liver impairment

72 tly greater need for mechanical ventilation, renal replacement therapy, and ICU stay in patients in t

73 d Chronic Health Evaluation II score, use of renal replacement therapy, and infection by nonfermentin

74 uring acute kidney injury, even with ongoing renal replacement therapy, and is sufficient to cause ac

75 Outcomes of AKI severity, requirement for renal replacement therapy, and mortality were also measu

76 Only 10 (11%) could provide renal replacement therapy, and only 18 (20%) provided an

77 ion and clearance profiles during continuous renal replacement therapy, and this knowledge is importa

78 entilation, frequency of vasopressor use and renal replacement therapy, and time to in-hospital clini

79 ath within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days wi

80 Patients receiving regional continuous renal replacement therapy anticoagulation with heparin a

81 The indication and timing of renal replacement therapy are controversially discussed.

82 raft futility (RAF-patient death or need for renal replacement therapy at 3 months) after simultaneou

83 negatively associated with the initiation of renal replacement therapy at admission.

84 ice was inserted preoperatively, or need for renal replacement therapy at any time postoperatively.

85 Death or renal-replacement therapy at 30 days occurred to a simil

86 and cardiogenic shock, the risk of death or renal-replacement therapy at 30 days, and mortality at 1

87 type 3 who developed AKI requiring prolonged renal replacement therapy because of severe renal inflam

88 Prolonged renal replacement therapy before kidney transplant incre

89 ransplantation is now an established form of renal replacement therapy, but the efficacy and safety o

90 Continuous renal replacement therapy can be used successfully in cr

91 /angiotensin II receptor blockers, lactates, renal replacement therapy, chronic heart disease, and in

92 voriconazole were cleared by the continuous renal replacement therapy circuit and clearance increase

93 ess dysfunction is a predictor of continuous renal replacement therapy circuit failure.

94 calcium anticoagulation prolongs continuous renal replacement therapy circuit life compared with reg

95 voir was connected to a pediatric continuous renal replacement therapy circuit programmed for a 10 kg

96 An ex vivo continuous renal replacement therapy circuit was used to evaluate d

97 ubjects who were treated with 857 continuous renal replacement therapy circuits (median 2 circuits pe

98 patients and from extracorporeal continuous renal replacement therapy circuits.

99 earance increased with increasing continuous renal replacement therapy clearance rates (7.66 mL/min,

100 nd did not change with increasing continuous renal replacement therapy clearance rates.

101 correlating with three different continuous renal replacement therapy clearance rates: 1) no clearan

102 67 mL/min, respectively, for high continuous renal replacement therapy clearance).

103 Median time to continuous renal replacement therapy commencement was 4 hours (inte

104 as significantly lower in patients requiring renal replacement therapy compared with those without re

105 Continuous renal replacement therapy (CRRT) benefits patients with

106 ill patients with requirement of continuous renal replacement therapy (CRRT) represent a growing int

107 In patients receiving continuous renal replacement therapy (CRRT), the concentrations of

108 ts were defined as a composite of mortality, renal replacement therapy-dependence or inability to rec

109 Continuous renal replacement therapy did not decrease platelets com

110 AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study a

111 o recover sufficient renal function allowing renal replacement therapy discontinuation when baseline

112 However, standard renal replacement therapy does not correct this defect i

113 Secondary end points included use of renal replacement therapy, duration of intensive care un

114 hirty-one patients (50.0%) were treated with renal replacement therapy during extracorporeal membrane

115 However, the necessity of renal replacement therapy during extracorporeal membrane

116 Renal replacement therapy during ICU stay and number of

117 ilation, days alive and free of vasopressor, renal replacement therapy during ICU stay, and length of

118 ection, vasoactive agent use, and receipt of renal replacement therapy during ICU stay.

119 sis might depend on the prompt initiation of renal replacement therapy-especially when liver failure

120 imated glomerular filtration rate (if not on renal replacement therapy) evaluated up to 90 days after

121 duration of mechanical ventilation, need for renal replacement therapy, extracorporeal life support o

122 The need for renal replacement therapy (five [3.2%] and six [3.9%] pa

123 critically ill patients requiring continuous renal replacement therapy for acute kidney injury.

124 and dialysis dependency after initiation of renal replacement therapy for acute kidney injury.

125 ts to indicate the earlier use of continuous renal replacement therapy for both renal dysfunction and

126 urrent evidence supporting best practices in renal replacement therapy for critically ill patients wi

127 certainties about the optimal application of renal replacement therapy for patients with acute kidney

128 There is no doubt that renal replacement therapy for the most severe forms of a

129 oneal dialysis (PD) is a life-saving form of renal replacement therapy for those with end-stage kidne

130 obal Outcomes 3 acute kidney injury received renal replacement therapy, for a median duration of 7 da

131 8 days, 60 days, and 1 year, renal recovery, renal replacement therapy free days, ICU-free days, and

132 dent association between RBC transfusion and renal replacement therapy-free days, mechanical ventilat

133 Time to initiate continuous renal replacement therapy from PICU admission was lower

134 Indices of continuous renal replacement therapy function representing 554,991

135 f impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large

136 re, mechanical ventilation, vasopressor use, renal replacement therapy, grade 3/4 hepatic encephalopa

137 ith acute kidney injury requiring continuous renal replacement therapy, greater than 10% fluid overlo

138 the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344

139 Prevention of hemodynamic instability during renal replacement therapy helped to achieve ultrafiltrat

140 mission post kidney transplantation, chronic renal replacement therapy (hemodialysis or peritoneal di

141 Future monitoring of continuous renal replacement therapy hemodynamics may facilitate re

142 icated by renal failure requiring continuous renal replacement therapy, hypertension (systolic blood

143 ompartment in 23 (9.4%) versus 9 (3.7%), and renal replacement therapy in 148 (58.5%) versus 99 (39.1

144 ve and free of ventilation, vasopressors and renal replacement therapy in 28-day and 1-year survivors

145 eiving continuous mechanical ventilation and renal replacement therapy in a long-term care hospital w

146 light on many areas of controversy regarding renal replacement therapy in acute kidney injury, provid

147 , parallel-group trial of two strategies for renal replacement therapy in critically ill patients wit

148 ive drugs were used in 23 patients (68%) and renal replacement therapy in eight patients (24%).

149 The guidelines for continuous renal replacement therapy in pediatric acute liver failu

150 e and free of ventilation, vasopressors, and renal replacement therapy in septic shock in 28-day surv

151 higher risk of acute kidney injury requiring renal replacement therapy in SOT vs. non-SOT patients (3

152 a substantial subgroup of patients requiring renal replacement therapy in the ICU.

153 tcome of these patients requiring continuous renal replacement therapy in the PICU.

154 syndrome, and acute kidney injury requiring renal replacement therapy in the two out of three patien

155 There was less use of renal replacement therapy in the vasopressin group than

156 mode, intensity, and duration of continuous renal replacement therapy in this setting are unknown.

157 A delayed strategy averted the need for renal-replacement therapy in an appreciable number of pa

158 The timing of renal-replacement therapy in critically ill patients who

159 Complications of renal replacement therapy include hemodynamic instabilit

160 These findings suggest that continuous renal replacement therapy initiated early and continued

161 ay increase from ICU admission to continuous renal replacement therapy initiation (p = 0.024).

162 e hundred thirty adult patients who required renal replacement therapy initiation in the ICU.

163 ed time between ICU admission and continuous renal replacement therapy initiation was also associated

164 A decrease in platelet values following renal replacement therapy initiation was associated with

165 mbocytopenia and platelet decrease following renal replacement therapy initiation were associated wit

166 s fluid balance from admission to continuous renal replacement therapy initiation, adjusted for body

167 had respiratory and hemodynamic supports at renal replacement therapy initiation, similarly distribu

168 factor, independent of timing of continuous renal replacement therapy initiation, that should be fur

169 increased already 5 days prior to continuous renal replacement therapy initiation.

170 ment therapy and platelet decrease following renal replacement therapy initiation.

171 ven after adjusting for timing of continuous renal replacement therapy initiation.

172 eplacement therapy (positive fluid balance x renal replacement therapy interaction (adjusted hazard r

173 he patients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopres

174 Acute kidney injury requiring continuous renal replacement therapy is a serious treatment-related

175 Acute kidney injury requiring renal replacement therapy is associated with high morbid

176 Continuous renal replacement therapy is associated with reduced amm

177 drug-circuit interactions during continuous renal replacement therapy is essential for appropriate d

178 the risk of mortality is high, especially if renal replacement therapy is needed.

179 ell transplant patients requiring continuous renal replacement therapy is sadly high.

180 uid overload at the initiation of continuous renal replacement therapy is the most important and earl

181 Continuous renal replacement therapy is valuable for surgical patie

182 e to initiate early and high-dose continuous renal replacement therapy led to increased survival with

183 r equal to 18 years old requiring continuous renal replacement therapy located in the ICU; 2) describ

184 or hospital length of stays, requirement for renal replacement therapy, longer duration of mechanical

185 is preferred initially (1D), but continuous renal replacement therapies may be considered if hemodia

186 Continuous renal replacement therapy may help reduce ammonia levels

187 ors, extracorporeal membrane of oxygenation, renal replacement therapy, mechanical ventilation, and/o

188 ered antimicrobials in an ex vivo continuous renal replacement therapy model.

189 Renal replacement therapy modified the association betwe

190 Rates of renal replacement therapy, mortality, and serious advers

191 s included limb ischemia, bleeding, need for renal replacement therapy, multiorgan failure, stroke or

192 Of patients receiving renal replacement therapy, neither positive (adjusted od

193 Acute kidney injury requiring renal replacement therapy occurred in 20% of SOTr compar

194 No differences in the need for renal replacement therapy, occurrence rate of myocardial

195 essin and its analogs had a reduced need for renal replacement therapy (odds ratio, 0.59 [0.37-0.92];

196 high-risk group were more likely to require renal replacement therapy (odds ratio, 10.4; 95% CI, 5.9

197 ptic or nonseptic causes and 2) the need for renal replacement therapy (odds ratio, 4.89; 3.83-6.28),

198 Data illustrate disparities in access to renal replacement therapy of any kind and in the use of

199 Little is known on the impact of continuous renal replacement therapy on antimicrobial dose requirem

200 In this study, we evaluate the effects of renal replacement therapy on subsequent platelet values,

201 ng Global Outcomes 3 defined by the need for renal replacement therapy or changes in urine output, se

202 Our primary endpoint was stage 3 AKI, renal replacement therapy or death within 7 days.

203 and low cardiac output syndrome but not for renal replacement therapy or deep sternal wound infectio

204 s type, length, site, and mode of continuous renal replacement therapy or international normalized ra

205 t least 40 hours apart, on treatment without renal replacement therapy or liver transplantation) or S

206 ney injury (serum creatinine > 354 umol/L or renal replacement therapy or minimum urine output < 0.3

207 osis was associated with a decreased risk of renal replacement therapy (OR, 0.26 [95% CI, 0.11-0.60])

208 HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90];

209 persisted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/mi

210 he hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum crea

211 ly affected by diurnal variation, continuous renal replacement therapy, or drugs.

212 ion in estimated glomerular filtration rate, renal replacement therapy, or renal death).

213 of death, stroke, myocardial infarction, new renal replacement therapy, or repeat revascularization.

214 nt was a composite of in-hospital mortality, renal replacement therapy, or severe right ventricular f

215 ipt of mechanical ventilation, vasopressors, renal replacement therapy, or vasodilator therapy.

216 ted glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (h

217 of the serum creatinine level, initiation of renal-replacement therapy, or death from renal disease)

218 p < 0.0001, p < 0.0001, and p = 0.0004), and renal replacement therapy (p = 0.0008, p = 0.0008, and p

219 udy site (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P =

220 s a smaller proportion of patients receiving renal-replacement therapy (P=0.04) and a shorter duratio

221 the short-term composite end point of death, renal-replacement therapy, perioperative myocardial infa

222 Even after 4 days of renal replacement therapy, plasma from patients with sep

223 Renal-replacement therapy poses several practical and et

224 , which was attenuated in those who received renal replacement therapy (positive fluid balance x rena

225 of AKI at 7 days, the need for postoperative renal replacement therapy, postoperative red blood cell

226 ation days and acute renal failure requiring renal replacement therapy predicted prolonged critical i

227 nths after transplant), a longer duration of renal replacement therapy pretransplant and the occurren

228 nal replacement therapy versus patients with renal replacement therapy prior to extracorporeal membra

229 sion analysis suggests that the necessity of renal replacement therapy prior to extracorporeal membra

230 development of acute kidney injury requiring renal replacement therapy prior to extracorporeal membra

231 criteria and 45 of these received continuous renal replacement therapy prior to transplantation or re

232 tions (mechanical ventilation, vasopressors, renal replacement therapy) provided in the ICU and outco

233 k for associated outcomes including need for renal replacement therapy, rehospitalization, and death,

234 Continuous renal replacement therapy renin removal was negligible (

235 had pre-existing ESRD and CKD not requiring renal replacement therapy, respectively.

236 opment of HUS (primary outcome) and need for renal replacement therapy (RRT) (secondary outcome) in S

237 Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney

238 Renal failure requiring renal replacement therapy (RRT) has detrimental effects

239 was an independent predictor of the need for renal replacement therapy (RRT) in the first month post-

240 opportunity to characterize the incidence of renal replacement therapy (RRT) initiation over the life

241 Although lifesaving in many situations, renal replacement therapy (RRT) may be associated with c

242 We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level a

243 Patients with established AKI requiring renal replacement therapy (RRT) were excluded.

244 eatinine clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to popul

245 eatinine clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to popul

246 od pressure (BP), decreased kidney function, renal replacement therapy (RRT), and death.

247 of AKI at 7 days, the need for postoperative renal replacement therapy (RRT), postoperative red blood

248 4%) stage III, and 25 patients (5%) required renal replacement therapy (RRT).

249 care unit admission (69%), intubation (65%), renal replacement therapy (RRT; 33%), and mortality (42%

250 significant reduction in the requirement of renal replacement therapy (RRT; 56.6% vs. 80%; P = 0.006

251 turia to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney rep

252 vents were renal (incident renal failure and renal replacement therapy [RRT]) and bone events (incide

253 Acute renal replacement therapies (RRTs), including ultrafiltr

254 Five independent continuous renal replacement therapy runs were performed to assess

255 derwent a total of 78 prolonged intermittent renal replacement therapy sessions, 39 in each arm.

256 ative extracorporeal membrane oxygenation or renal replacement therapy, severe preimplant tricuspid r

257 Continuous renal replacement therapy should be considered at an ear

258 eceive a liver transplant, use of continuous renal replacement therapy significantly improved surviva

259 emia by 48 hours after initiating continuous renal replacement therapy significantly improved surviva

260 ion of these interventions and/or continuous renal replacement therapy-specific deliverables was inco

261 of the Acute Renal Failure Trial Network and RENAL Replacement Therapy Study Investigators trials.

262 om the Acute Renal Failure Trial Network and RENAL Replacement Therapy Study trials were used.

263 o end-stage kidney disease (ESKD), requiring renal replacement therapy, such as dialysis.

264 component composite of death through day 30, renal-replacement therapy through day 30, perioperative

265 occurrence of acute kidney injury, need for renal-replacement therapy, time to target temperature, a

266 requiring either intermittent or continuous renal replacement therapy) to $876,539 (data from an acu

267 n event requiring vasopressor and continuous renal replacement therapy tube disconnection, pooled occ

268 We aimed to study continuous renal replacement therapy use in acute liver failure pat

269 yzed for patient characteristics, continuous renal replacement therapy use, ammonia dynamics, and out

270 , duration of mechanical ventilation, use of renal replacement therapy, use of vasopressors and inotr

271 Continuous renal replacement therapy using blood flow rate set at 2

272 Renal replacement therapy variables, demographic, clinic

273 differed significantly for patients without renal replacement therapy versus patients with renal rep

274 U mortality of patients requiring continuous renal replacement therapy was 54.4% (37/68 patients).

275 eline thrombocytopenia in patients requiring renal replacement therapy was associated with increased

276 Renal replacement therapy was needed in 23% and inotrope

277 Continuous renal replacement therapy was not an independent predict

278 Continuous renal replacement therapy was performed in the hemodiafi

279 Time from diagnosis of AAN to renal replacement therapy was relatively short (1 [0-15]

280 emodynamic support, respiratory support, and renal replacement therapy was reported in six of 15 rand

281 cute renal failure study in which continuous renal replacement therapy was the most expensive therapy

282 in serum creatinine or a new requirement for renal replacement therapy was within the protocol-define

283 2 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03

284 With the delayed strategy, renal-replacement therapy was initiated if at least one

285 Renal-replacement therapy was initiated in 13 of 4687 pa

286 of death or severe renal failure leading to renal-replacement therapy was lower among those who init

287 With the early strategy, renal-replacement therapy was started immediately after

288 acute kidney injury treated with continuous renal replacement therapy, we found no association of RB

289 % CI, 1.86-23.08) at the start of continuous renal replacement therapy were associated with PICU mort

290 e and free of ventilation, vasopressors, and renal replacement therapy were highly significantly asso

291 0 evaluable patients who received continuous renal replacement therapy were included.

292 Invasive positive pressure ventilation and renal replacement therapy were used in only 34.6% and 11

293 l disease in the United States without prior renal replacement therapy who had incident vascular acce

294 ney injury undergoing prolonged intermittent renal replacement therapy with cooler dialysate experien

295 e randomized to start prolonged intermittent renal replacement therapy with dialysate temperature of

296 any cause or severe renal failure leading to renal replacement therapy within 30 days.

297 of death or severe renal failure leading to renal-replacement therapy within 30 days after randomiza

298 nsisted of a composite end point of death or renal-replacement therapy within 30 days and mortality w

299 50% above first value or initiation of acute renal-replacement therapy, within the first 5 days of ho

300 Continuous renal replacement therapy without anticoagulation was mo